Watch long acting B2 agonist cardiac risk in the first month


eMediNexus    05 January 2018

The risk for CVD in COPD increased approximately 1.5-fold during the first 30 days after starting therapy with long-acting β2 agonists compared with ongoing or more prolonged use, lead author, Meng-Ting Wang, PhD, and coauthors write in JAMA Internal Medicine.

Doctors should be very vigilant with regard to any cardiovascular symptoms within 30 days of initiating LABA or LAMA treatment for COPD.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.